Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bone Biologics Corp (BBLG)

Bone Biologics Corp (BBLG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,342
  • Shares Outstanding, K 1,801
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,950 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +13.33%
on 10/29/24
2.3000 -40.87%
on 10/18/24
-0.4200 (-23.60%)
since 10/08/24
3-Month
0.8000 +70.00%
on 09/13/24
2.7500 -50.55%
on 09/25/24
-0.2300 (-14.47%)
since 08/08/24
52-Week
0.8000 +70.00%
on 09/13/24
10.5600 -87.12%
on 12/28/23
-2.8704 (-67.85%)
since 11/08/23

Most Recent Stories

More News
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first...

BBLG : 1.3600 (+4.62%)
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s...

BBLG : 1.3600 (+4.62%)
Bone Biologics CEO Issues Letter to Stockholders

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer,...

BBLG : 1.3600 (+4.62%)
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units...

BBLG : 1.3600 (+4.62%)
WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

/PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics...

BBLG : 1.3600 (+4.62%)
Bone Biologics Prices $5,100,000 Million Underwritten Public Offering

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities...

BBLG : 1.3600 (+4.62%)
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer,...

BBLG : 1.3600 (+4.62%)
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer,...

BBLG : 1.3600 (+4.62%)
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that it closed a public offering of 1,510,455...

BBLG : 1.3600 (+4.62%)
WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering

/PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of an...

BBLG : 1.3600 (+4.62%)

Business Summary

Bone Biologics Corp. is a developer of orthobiologic products for spine fusion markets. Bone Biologics Corp. is based in BURLINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 1.4733
2nd Resistance Point 1.4267
1st Resistance Point 1.3933
Last Price 1.3600
1st Support Level 1.3133
2nd Support Level 1.2667
3rd Support Level 1.2333

See More

52-Week High 10.5600
Fibonacci 61.8% 6.8317
Fibonacci 50% 5.6800
Fibonacci 38.2% 4.5283
Last Price 1.3600
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar